Trending 
Trending
Copied ₹2.9683
₹ 2.9683
Market Cap
₹ 6.06 B 3.7587%
Circulating Supply
2145030000
Max Supply
3320000000
Volume
₹ 1.12 B
All Time High :
₹ 76.28
All Time Low :
₹ 1.49
Price change in 24H :
₹ 0
24H High :
₹ 2.8
24H Low :
₹ 2.71
Token distribution
Bio Protocol is a decentralized science (DeSci) platform that uses blockchain to fund, govern, and commercialize biotechnology research. It operates as a coordination and funding layer for BioDAOs, community-owned research organizations focused on specific conditions that tokenize intellectual property as IP-NFTs and raise capital through on-chain auctions called Ignition Sales. Its native token, BIO, provides meta-governance across all BioDAOs from a single token, plus curation staking and launchpad access. Backed by Binance Labs, Maelstrom Fund, and Animoca Brands, the protocol has facilitated over $50 million in research funding and launched three AI "BioAgents." BIO trades near $0.026 with a market capitalization around $55–70 million, roughly 97% below its all-time high of about $0.88.
Understanding Bio Protocol requires understanding the problem it addresses, because the thesis is genuinely coherent even where the token performance has not been.
The core issue: pharmaceutical returns on new drugs have been declining for decades. It has become too risky for pharma companies to back most early-stage science, particularly in new or emerging fields. As a result, valuable scientific research frequently never leaves academia, or takes more than ten years and billions of dollars to reach patients.
Researchers depend on universities, government grants, private companies or venture capital, all of which have specific size thresholds and risk tolerances. Research below a certain commercial scale, or in an unfashionable area, or targeting a rare condition, simply does not get funded.
Decentralized science (DeSci) proposes an alternative: use blockchain and tokenization to enable scientific funding, data sharing and collaboration outside traditional science's target size and risk profile. If a global community of patients, researchers and investors can pool capital and govern research directly, projects that fall below institutional thresholds become fundable.
Bio Protocol's role is the financial and coordination layer for that system routing resources to promising scientific IP on-chain.
The foundational unit. A BioDAO is a community-owned organization focused on a specific therapeutic area or scientific domain. Members pool capital, vote on which research to fund, and share in any upside from resulting intellectual property.
Existing BioDAOs in the ecosystem cover areas including longevity (VitaDAO), hair loss (HairDAO), men's health, and microbiome health, among others.
Each BioDAO has its own token, governance, and portfolio of research. Bio Protocol connects them.
Research output patents, data, and licensing rights are tokenized as intellectual property NFTs. This converts something historically illiquid and trapped inside institutions into an asset that can be owned fractionally, traded, and governed by its holders.
Token holders then govern licensing decisions and share in the allocation of IP licensing and acquisition proceeds.
New BioDAOs raise capital through Ignition Sales; on-chain auctions and bonding curve mechanisms that mint DAO tokens and IP-NFTs.
Critically for tokenomics: each new project requires BIO for participation in Ignition Sales and for liquidity pairing. This creates direct transactional demand for BIO tied to ecosystem growth rather than to speculation alone.
1. Funding. BIO holders vote to direct funding to specific IP assets, reward BioDAOs for minting IP tokens, or fund community and infrastructure initiatives.
2. Meta-governance. This is the most distinctive design feature. A single BIO token confers voting power across multiple BioDAOs simultaneously. Holders can govern a wide range of DeSci organizations without choosing a specific therapeutic area, voting on IP tokenization, data-sharing policies, and allocation of licensing proceeds across the whole portfolio.
The project's own framing calls this making BIO a "gateway drug" to DeSci: broad exposure to the sector without needing to pick winners.
3. Curation and access. Staking BIO signals which BioDAOs deserve support, earns whitelist access to BioDAO funding rounds, and determines allocation in launch competitions.
Locked BIO becomes vBIO, used to vote on which BioDAO proposals join the accelerator, with bonus rewards when backed proposals are selected.
The most significant strategic development in the protocol's history, and the reason BIO now appears in AI-token discussions as well as DeSci ones.
Bio V2 introduced BioAgents, autonomous AI co-scientists capable of generating hypotheses, designing experiments, and managing fund flows through on-chain wallet interactions.
The concept is that AI agents can perform the scientific knowledge work that currently bottlenecks research: literature synthesis, hypothesis generation, and experimental design. If an agent can do that autonomously and hold a wallet, it can, in principle, run a research program with community oversight rather than institutional employment.
The first BioAgent, "Aubrai," launched in partnership with VitaDAO in August 2025, trained on longevity researcher Aubrey de Grey's lab data and community insights.
As of 2026, three BioAgents have launched, covering longevity, men's health, and microbiome health, with additional agents being deployed by BioDAOs across the ecosystem and in partnership with researchers.
The token mechanic: users can stake BIO to run BioAgents locally or in the cloud and earn yield. This ties token demand to computational participation rather than passive holding.
Launched 20 June 2026, OpenLabs is an AI research hub integrating AI tools, community funding and governance into a single interface. It is explicitly positioned to replace traditional grant applications, researchers develop ideas, coordinate with contributors and seek funding through community voting powered by BIO.
Notably, BIO fell 8% on the day of the OpenLabs launch. That reaction is worth recording, because it demonstrates something important: product announcements alone have stopped moving this token. Sustained adoption, not launches, is what the market is now pricing.
A live demo on 12 May 2026 showcased biotech tool integrations and segmentation capabilities for research workflows, validating progress on the AI tooling rather than announcing a finished product.
Circulating supply: approximately 2.15 billion BIO
Total supply: approximately 3.32 billion BIO
Chains: Ethereum, Solana, and Base, with native and Wormhole bridge routes
A detail that deserves attention: in October 2025, circulating supply was reported at approximately 1.69 billion against a total of 3.06 billion. By late 2026 those figures were roughly 2.15 billion and 3.32 billion.
That represents circulating supply expanding by roughly 27% in under a year, with total supply also rising. For a token whose price fell over the same period, ongoing supply expansion is a material headwind that most coverage of Bio Protocol does not mention.
Over 125 million BIO is staked approximately 3.5% of circulating supply.
This is low. For comparison, protocols with strong staking economics typically see 20–50% of supply locked. A 3.5% participation rate suggests either that staking rewards are insufficiently attractive relative to holding liquid, or that holders are unwilling to lock a volatile asset.
BioXP Season 2 updated the rewards system to tie XP earnings solely to staking, removing rewards previously available for social engagement, colloquially "yapping." That is a sensible correction: paying for posts attracts mercenary attention, while paying for locked capital attracts commitment. Whether it lifts the participation rate is unproven.
Bio Protocol has assembled a notably credible backer list for a project in an experimental sector.
Binance Labs backed the protocol in November 2024, which industry coverage treated as significant validation of the DeSci model generally, not just of Bio specifically.
September 2025; a $6.9 million funding round led by Maelstrom Fund, with Animoca Brands also participating. The capital was earmarked for development and promotion of Bio V2, the AI-native DeSci platform.
Maelstrom is the family office of Arthur Hayes, BitMEX co-founder, and its involvement drew substantial crypto-media attention. Animoca is among the most active strategic investors in Web3.
Capital deployed into science:
Over $33 million raised via the BIO Genesis initiative
Over $50 million in research funding facilitated since Genesis
That second figure is the one that matters most for evaluating whether DeSci is real. Fifty million dollars deployed into actual biotech research is not a rounding error, and it distinguishes Bio Protocol from projects whose "real-world impact" exists only in marketing copy.
BIO trades near $0.026 as of mid-September 2026, though quoted figures diverge across providers; CoinGecko around $0.0267, CoinMarketCap around $0.0252, CryptoRank around $0.0334, and Coinbase around $0.0247.
Market capitalization falls roughly in the $55–70 million range depending on which price and supply figures are used.
Late 2024 — Token launch via airdrop to DeSci early adopters, followed by the BIO Genesis bootstrapping phase.
Peak: approximately $0.88.
October 2025 — Trading near $0.087 with a market cap around $267 million on 1.69 billion circulating.
March 2026 — Down over 90% from peak, to approximately $0.018.
16 April 2026 — A sharp rally to $0.038, up 52% in 24 hours. Volume that day reached $726 million against a roughly $70 million market cap — a 10x turnover ratio. Turnover at that level is not organic accumulation; it is intense short-term speculation.
Context for that rally: the DeSci sector had reached a $315 million market cap, with BIO holding close to a 20% share and functioning as the liquidity anchor for BioDAOs across the ecosystem. Capital was rotating from memecoins into utility-focused tokens.
September 2026 — Approximately $0.027, up roughly 4.5% over seven days and 6.7% over thirty days. Down approximately 97% from the $0.88 peak, and down roughly 70% over twelve months.
A data-quality flag: at least one automated source reports an "82% drawdown from all-time high," which cannot be reconciled with a $0.88 peak and a $0.026 current price that combination implies roughly 97%. Verify drawdown figures against the underlying price history rather than trusting a single stated percentage.
DeSci is a small sector, and the projects within it occupy genuinely different positions.
The key structural distinction: VitaDAO, HairDAO and similar organisations are individual research DAOs with a specific therapeutic focus. Bio Protocol is the layer beneath them, it does not run research itself, it funds and coordinates those that do.
That makes BIO an index-like exposure to DeSci rather than a bet on any single scientific thesis. The project's own "gateway drug" framing captures it: you get breadth without picking a condition.
The trade-off is real. Index exposure means BIO cannot outperform on a single breakthrough the way a focused DAO could, if VitaDAO's longevity research produces a result, VitaDAO captures most of that upside. BIO captures a diluted share across a portfolio. It also means BIO absorbs the whole sector's weakness, which is what the past twelve months demonstrated.
There are four distinct roles, with meaningfully different risk profiles.
As a governance participant. Acquire BIO and lock it as vBIO to vote on which BioDAO proposals join the accelerator, on IP tokenization policy, data-sharing rules, and allocation of licensing proceeds. This is the role the token was primarily designed for.
As a launchpad participant. Stake BIO to earn whitelist access and allocation in BioDAO funding rounds and Ignition Sales. BioXP Season 2 ties XP and therefore allocation solely to staking.
As a BioAgent operator. Stake BIO to run BioAgents locally or in the cloud and earn yield. This is the most technically involved role and the one most directly tied to the protocol's AI thesis.
As a researcher. Through OpenLabs, develop ideas, coordinate with contributors and seek funding through community voting bypassing the traditional grant application process entirely. This is the role that determines whether any of the above has value.
A practical caution. Every participation route other than the last requires holding a volatile small-cap token, and several require locking it. Staking rewards denominated in BIO mean that if the token falls during a lock, both the principal and the yield depreciate together. The 97% drawdown from peak illustrates how severe that compounding can be.
Scientific timeline risk, the dominant one. Biotech research takes years to produce results, and clinical validation takes longer still. DeSci was created to compress those timelines, but compressing drug development is a far harder problem than funding it. Token holders are being asked for patience measured in years, not quarters.
Supply expansion. Circulating supply grew roughly 27% in under a year while price fell. Continued emissions are a persistent mechanical headwind independent of any news.
Sector concentration. BIO holds close to a 20% share of a $315 million sector. It is the leader of something small, and DeSci-wide sentiment shifts move BIO more than anything the protocol itself does.
Regulatory exposure. Tokenized intellectual property, community-funded research and AI-driven drug discovery each sit in unsettled regulatory territory. As AI governance tightens in healthcare and biotech, safety-review infrastructure becomes a prerequisite for institutional trust, and a compliance cost.
Weak staking participation. At 3.5%, the token is largely held liquid rather than committed, which means less supply is insulated from selling pressure than the staking design intends.
Narrative dependency. BIO has rallied on sector rotation and fallen with it, with an April 2026 turnover ratio of 10x market cap. Assets that trade on narrative are repriced when narrative moves, regardless of execution.
Execution risk on AI claims. BioAgents are a genuinely ambitious technical proposition. Three are live, which is evidence of substance, but autonomous hypothesis generation and experimental design are unsolved problems in AI research generally, not just in crypto.
The most significant market event of the year for Bio Protocol, and a useful case study in how narrative sectors behave.
In April 2026, overall crypto market activity was subdued, with Bitcoin and Ethereum trading in narrow ranges. Against that backdrop, the DeSci sector broke out distinctly, reaching a $315 million aggregate market cap, with BIO holding a near-20% share.
Several catalysts converged:
The $6.9 million Maelstrom-led round for Bio V2 development
BioXP Season 2 launching, requiring users to stake BIO to participate in rewards and allocation competitions, reducing circulating supply
BioAgents launching on Bio V2, uniting AI, biotech, and on-chain infrastructure into a single coherent narrative
The ADHD peptide announcement from an ecosystem DAO, tapping into AI-driven drug discovery momentum
BIO rallied 52% in a day to $0.038, with $726 million in volume against a $70 million market cap.
The honest reading: a 10x volume-to-market-cap ratio indicates a token being traded intensively rather than accumulated. Sector rotations of this kind lift high-beta names violently and retreat equally fast. BIO has since given back most of that move, trading near $0.027.
What it does prove: BIO retains genuine beta to DeSci sentiment. When the sector moves, BIO moves hardest. That is useful to know and equally useful to be cautious about.
Bio Protocol's 2026 roadmap centers on three pillars: building AI-native infrastructure, enhancing cross-chain governance, and scaling the BioDAO ecosystem. AI integration is explicitly identified as the most significant growth lever.
Why the pivot makes strategic sense. DeSci's original bottleneck was capital connecting funding to under-resourced research. But capital alone does not accelerate science; the scarce resource is expert time. If BioAgents can genuinely perform hypothesis generation, experimental design and literature synthesis, they address the actual constraint rather than the funding one.
Why it carries risk. "AI agent" is the most heavily used narrative in crypto during this period, and attaching it to an existing project invites skepticism about whether the integration is substantive or positioning. The three launched BioAgents and the BIOS live demo suggest substance. The 8% price drop on OpenLabs launch day suggests the market is not taking announcements at face value.
The regulatory dimension. As AI governance tightens in healthcare and biotech, establishing infrastructure for safety reviews becomes essential to building institutional trust in AI-driven discovery. That is a meaningful hurdle for any BioDAO progressing toward clinical validation and clinical validation is where DeSci's thesis ultimately has to prove itself.
Since early 2025, Bio Protocol has expanded from a single-chain Ethereum deployment to a multichain architecture spanning Ethereum, Solana and Base, with core modules including the BioDAO launchpad and liquidity engine going live progressively.
Solana expansion in particular broadens access to a large retail base with low transaction costs relevant for a protocol whose thesis depends on wide participation in funding and governance rather than a small number of large allocators.
Bio Protocol functions as the liquidity anchor for BioDAOs across the DeSci sector. Other participants include VitaDAO (longevity), HairDAO, Vibe, and ResearchCoin (RSC).
BIO's near-20% share of a $315 million sector makes it the sector's bellwether: BIO's performance is substantially a proxy for DeSci sentiment as a whole, which cuts both ways.
No separate foundation entity has been identified. Bio Protocol operates through on-chain governance by BIO token holders, using the meta-governance structure described above, where a single token confers voting rights across multiple BioDAOs.
Individual BioDAOs within the ecosystem have their own governance structures and, in some cases, their own legal wrappers appropriate to holding and licensing intellectual property. That is a necessity rather than a choice: IP ownership requires a legal entity capable of holding it.
Four indicators matter more than price, and three of them are publicly observable.
Ignition Sale oversubscription. Each new BioDAO launch requires BIO for participation and liquidity pairing. Whether sales are oversubscribed is a direct, measurable read on real demand for BIO's utility rather than its narrative. An undersubscribed sale is a clearer negative signal than any price move.
Traditional co-investment. The single most important signal available. If an established pharmaceutical company, a major research institution, or a conventional biotech venture fund co-funds a BioDAO project alongside community capital, it validates the model in a way no on-chain metric can. It would also distinguish this DeSci cycle decisively from the 2024–25 hype phase. Nothing of that kind has been prominently reported yet.
BioAgent output quality. Three agents are live. The question is whether they produce hypotheses or experimental designs that working researchers actually adopt. An AI co-scientist nobody uses is a demo; one that generates a published result is infrastructure.
Supply schedule. With circulating supply having expanded 27% in a year and roughly 1.17 billion tokens still outside circulation, the emission path is a mechanical determinant of price pressure. Anyone sizing a position should map it rather than assume it has finished.
What is notably absent from the bear case: there is no allegation of fraud, no exploit, no abandoned development, no anonymous team, and no rug. Bio Protocol is shipping products, deploying capital into research, and expanding across chains. The difficulty is that its core promise, accelerating science is one that cannot be verified on the timescale token markets operate on.
What is genuinely working:
Over $50 million in research funding facilitated and $33 million+ was raised through BIO Genesis real capital deployed into real science. Backing Binance Labs, Maelstrom Fund, and Animoca Brands. Three live BioAgents across longevity, men's health, and microbiome health. Multichain deployment across Ethereum, Solana, and Base. A functioning launchpad with Ignition Sales creating transactional BIO demand. A coherent thesis addressing a real failure in biotech funding. Near 20% share of the DeSci sector.
What is not:
Down roughly 97% from the $0.88 peak and 70% over twelve months. Circulating supply expanded roughly 27% in under a year while price fell. Only 3.5% of supply staked weak participation. Product launches no longer move price; OpenLabs fell 8% on launch day. April's rally came with a 10x turnover ratio characteristic of speculation rather than accumulation. And the entire sector sits at a $315 million market cap, meaning even sector leadership is leadership of something small.
The structural question and it is the honest one. DeSci's thesis will be validated or falsified by scientific outcomes, not token prices. The question is not whether BIO can rally on narrative rotation; it demonstrably can. The question is whether the $50 million deployed produces a drug, a therapy, a licensing deal or a clinical result that would not otherwise have existed.
That answer is years away. Biotech timelines are measured in the same decade-long increments that DeSci was created to compress, and compressing them is a far harder problem than funding them. A protocol can route capital efficiently and still discover that the bottleneck was never capital.
What would change the picture: attracting co-investment from traditional biotech or academic institutions is the clearest available signal separating this DeSci cycle from the previous hype phase. If established pharma or a major research institution co-funds a BioDAO project, it validates the model in a way no token metric can.
This is not financial advice. BIO is a small-cap token in an experimental sector, trading far below its peak, with ongoing supply expansion and heavy dependence on sector sentiment.
A decentralized science (DeSci) platform that uses blockchain to fund, govern, and commercialize biotechnology research. It acts as the coordination and funding layer for BioDAOs community-owned research organizations that tokenize intellectual property and raise capital through on-chain auctions.
Decentralized science using blockchain and DAOs to fund, share, govern, and commercialize research outside traditional institutional channels. It targets research that falls below the size or risk thresholds of universities, government grants, pharma, or venture capital.
A community-owned organization focused on a specific scientific or therapeutic area. Members pool capital, vote on which research to fund, and share in upside from resulting intellectual property. Examples include VitaDAO (longevity) and HairDAO.
Three main functions: directing funding to specific IP assets and BioDAOs; meta-governance, where one token confers voting rights across multiple BioDAOs simultaneously; and curation staking for whitelist access and allocation in BioDAO funding rounds. BIO is also required for participation in Ignition Sales and for liquidity pairing.
Bio Protocol's most distinctive design feature. Rather than needing separate tokens for each BioDAO, a single BIO token lets holders vote across the whole ecosystem on IP tokenization, data-sharing policies, and allocation of licensing proceeds giving broad sector exposure without choosing a therapeutic area.
A tokenized piece of intellectual property patents, research data or licensing rights converted into an on-chain asset that can be owned fractionally, traded and governed by holders, who then share in licensing and acquisition proceeds.
Autonomous AI "co-scientists" introduced with Bio V2, capable of generating hypotheses, designing experiments and managing fund flows through on-chain wallets. The first, "Aubrai," launched with VitaDAO in August 2025, trained on longevity researcher Aubrey de Grey's lab data. Three are live, covering longevity, men's health and microbiome health.
Users can stake BIO to run BioAgents locally or in the cloud and earn yield, tying token demand to computational participation rather than passive holding.
An AI research hub launched 20 June 2026, integrating AI tools, community funding and governance into one interface, positioned to replace traditional grant applications. Notably, BIO fell 8% on launch day.
On-chain auctions and bonding curve mechanisms through which new BioDAOs raise capital, minting DAO tokens and IP-NFTs. Participation requires BIO, creating direct transactional demand.
Binance Labs backed the protocol in November 2024. In September 2025 it raised $6.9 million in a round led by Maelstrom Fund, with Animoca Brands participating, earmarked for Bio V2 development.
Over $50 million in research funding facilitated, with more than $33 million raised through the BIO Genesis initiative.
Over 125 million BIO; approximately 3.5% of circulating supply. This is low relative to protocols with strong staking economics, which typically see 20–50% locked.
Approximately $0.88. At around $0.026, BIO trades roughly 97% below that. Note that at least one automated source reports an 82% drawdown, which cannot be reconciled with those two figures, verify against the underlying price history.
Ethereum, Solana and Base, with native and Wormhole bridge routes between them. It expanded from a single-chain Ethereum deployment beginning in early 2025.
No separate foundation entity has been identified. Governance runs on-chain through BIO token holders using the meta-governance structure. Individual BioDAOs may maintain their own legal wrappers, which IP ownership requires.
Several factors: the broader collapse in narrative-driven token valuations after the DeSci hype cycle, circulating supply expanding roughly 27% in under a year, weak staking participation at 3.5%, and the reality that scientific outcomes the thing that would validate the thesis take years to materialize.
Not financial advice. The considerations: real capital deployed into science, credible backers, a coherent thesis and sector leadership against a 97% drawdown, ongoing supply expansion, low staking participation, product launches that no longer move price, and a DeSci sector totalling only $315 million. The thesis will be settled by scientific results, which are years away.
Attracting co-investment from traditional biotech or academic institutions, and ultimately producing a drug, therapy, licensing deal or clinical result that would not otherwise have existed. Token metrics cannot validate the model; outcomes can.
